Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Lortholary · SciRah

Researcher profile · Semantic Scholar

A. Lortholary

Share profile

A. Lortholary — researcher profile on SciRah

h-index: 44
Works: 242
Citations: 12K

Most-cited papers

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
I. Ray-Coquard, P. Pautier, S. Pignata, D. Pérol +26 more
2019New England Journal of Medicine1,702 citations Open access
Semantic Scholar
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet +26 more
2023Annals of Oncology357 citations Open access
Semantic Scholar
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
F. Bidard, A. Hardy-Bessard, F. Dalenc, T. Bachelot +30 more
2022The Lancet Oncology273 citations Open access
Semantic Scholar
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
A. du Bois, G. Kristensen, I. Ray-Coquard, A. Reuss +23 more
2016The Lancet Oncology202 citations Open access
Semantic Scholar
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
X. Pivot, G. Romieu, M. Debled, J. Pierga +330 more
2019The Lancet117 citations Open access
Semantic Scholar
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew, B. Kaufman, Susana Banerjee, A. Lortholary +14 more
2019Annals of Oncology90 citations Open access
Semantic Scholar
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial
G. Falchook, Robert L. Coleman, A. Roszak, K. Behbakht +22 more
2019JAMA Oncology83 citations Open access
Semantic Scholar
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing
E. Girard, Séverine Eon-Marchais, R. Olaso, A. Renault +60 more
2018International Journal of Cancer71 citations Open access
Semantic Scholar
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
N. Mavaddat, A. Antoniou, T. Mooij, M. Hooning +52 more
2020Breast Cancer Research64 citations Open access
Semantic Scholar
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
O. Colomban, M. Tod, A. Leary, I. Ray-Coquard +9 more
2019Clinical Cancer Research63 citations
Semantic Scholar
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
P. Heudel, M. Fabbro, C. Roemer-Bécuwe, M. Kaminsky +17 more
2017British Journal of Cancer61 citations Open access
Semantic Scholar
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial.
C. Falandry, F. Rousseau, M. Mouret-Reynier, F. Tinquaut +16 more
2021JAMA Oncology60 citations Open access
Semantic Scholar
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
W. Jacot, P. Cottu, F. Berger, C. Dubot +15 more
2019Breast Cancer Research57 citations Open access
Semantic Scholar
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
F. Joly, D. Ahmed-Lecheheb, E. Kalbacher, N. Heutte +26 more
2019Annals of Oncology54 citations Open access
Semantic Scholar
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study
Lieske H. Schrijver, A. Antoniou, Hampus Olsson, T. Mooij +133 more
2021American Journal of Obstetrics and Gynecology52 citations Open access
Semantic Scholar
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
I. Ray-Coquard, A. Leary, S. Pignata, C. Cropet +16 more
2022Annals of Oncology45 citations Open access
Semantic Scholar
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
M. Friedlander, K. Moore, N. Colombo, G. Scambia +19 more
2021The Lancet Oncology44 citations
Semantic Scholar
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
F. Blanc-Durand, E. Yaniz-Galende, A. Llop-Guevara, C. Genestie +20 more
2023Gynecologic Oncology34 citations Open access
Semantic Scholar
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
S. Pignata, M. Bookman, J. Sehouli, A. Miller +21 more
2023Gynecologic Oncology31 citations
Semantic Scholar
Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
S. Caputo, L. Golmard, M. Léoné, F. Damiola +156 more
2021American Journal of Human Genetics30 citations Open access
Semantic Scholar
Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study
J. Ferrero, A. Hardy-Bessard, O. Capitain, A. Lortholary +7 more
2016Cancer29 citations Open access
Semantic Scholar
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.
C. Falandry, A. Savoye, L. Stefani, F. Tinquaut +16 more
2019Journal of Clinical Oncology27 citations
Semantic Scholar
Efficacy of anthracycline/taxane‐based neo‐adjuvant chemotherapy on triple‐negative breast cancer in BRCA1/BRCA2 mutation carriers
L. Bignon, J. Fricker, C. Noguès, E. Mouret-Fourme +11 more
2018The Breast Journal27 citations Open access
Semantic Scholar
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
F. Penault-Llorca, F. Kwiatkowski, A. Arnaud, C. Lévy +17 more
2019Breast23 citations Open access
Semantic Scholar
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
C. Lee, R. Asher, M. Friedlander, V. Gebski +10 more
2019European Journal of Cancer23 citations
Semantic Scholar
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Patrick Robelin, M. Tod, O. Colomban, J. Lachuer +17 more
2020Gynecologic Oncology17 citations Open access
Semantic Scholar
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families
A. Renault, N. Mebirouk, Eve Cavaciuti, Dorothée Le Gal +26 more
2017Carcinogenesis17 citations Open access
Semantic Scholar
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
G. Ferron, G. de Rauglaudre, S. Becourt, N. Delanoy +28 more
2023Gynecologic Oncology16 citations
Semantic Scholar
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
B. You, L. van Wagensveld, M. Tod, G. Sonke +16 more
2022British Journal of Cancer15 citations Open access
Semantic Scholar
Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
Yue Jiao, T. Truong, Séverine Eon-Marchais, N. Mebirouk +56 more
2022European Journal of Cancer15 citations Open access
Semantic Scholar
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
B. Lim, D. Potter, M. Salkeni, P. Silverman +15 more
2021Clinical Cancer Research15 citations
Semantic Scholar
Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.
F. Blanc-Durand, E. Yaniz, C. Genestie, E. Rouleau +16 more
202115 citations
Semantic Scholar
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
G. Ferron, G. de Rauglaudre, A. Chevalier, P. Combe +16 more
2019Journal of Clinical Oncology15 citations
Semantic Scholar
AXIN2 germline testing in a French cohort validates pathogenic variants as a rare cause of predisposition to colorectal polyposis and cancer
J. Leclerc, Marie Beaumont, Roseline Vibert, S. Pinson +23 more
2022Genes, Chromosomes and Cancer14 citations Open access
Semantic Scholar
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
F. Joly, M. Fabbro, D. Berton, J. Lequesne +23 more
2022Gynecologic Oncology14 citations Open access
Semantic Scholar
Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
Quentin Jacquinot, S. Paget-Bailly, P. Fumoleau, G. Romieu +8 more
2018Breast13 citations
Semantic Scholar
PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.
F. Bidard, R. Sabatier, F. Berger, B. Pistilli +16 more
201813 citations
Semantic Scholar
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.
L. Cabel, S. Delaloge, A. Hardy-Bessard, F. André +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation
Maximiliano Ribeiro Guerra, Juliette Coignard, Séverine Eon-Marchais, Marie-Gabrielle Dondon +48 more
2021Breast Cancer Research12 citations Open access
Semantic Scholar
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
T. van Gorp, M. Mirza, A. Lortholary, D. Cibula +16 more
2021Journal of Clinical Oncology12 citations
Semantic Scholar
Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.
J. Ledermann, A. Lortholary, R. Penson, E. Gibbs +16 more
201711 citations
Semantic Scholar
Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
Elsa Nigon, C. Lefeuvre-plesse, Alejandra Martinez, C. Chauleur +12 more
2023Journal of Translational Medicine10 citations Open access
Semantic Scholar
ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy.
I. Ray-Coquard, A. Leary, F. Bigot, L. Montané +16 more
202110 citations
Semantic Scholar
815MO The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
B. You, L. van Wagensveld, M. Tod, G. Sonke +15 more
202010 citations Open access
Semantic Scholar
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
F. Derquin, A. Floquet, A. Hardy-Bessard, J. Edeline +28 more
2020Gynecologic Oncology10 citations Open access
Semantic Scholar
“Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”
F. Gernier, D. Ahmed-Lecheheb, P. Pautier, A. Floquet +23 more
2021BMC Cancer9 citations Open access
Semantic Scholar
Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial.
P. Pujol, L. Roca, A. Lortholary, C. Lasset +16 more
20209 citations
Semantic Scholar
Quality of advanced ovarian cancer surgery: A French assessment of ESGO quality indicators.
Marie-Mélanie Gac, C. Loaec, Johanna Silve, E. Vaucel +13 more
2020European Journal of Surgical Oncology9 citations
Semantic Scholar
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
A. Hardy-Bessard, F. Brocard, F. Clatot, A. Lortholary +11 more
2020Breast9 citations Open access
Semantic Scholar
Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
O. Colomban, M. Tod, A. Leary, I. Ray-Coquard +9 more
2019Annals of Oncology9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

I. Ray-Coquard×14
Invite
I. Ray-Coquard — researcher profile on SciRah
L. Venat-Bouvet×11
Invite
L. Venat-Bouvet — researcher profile on SciRah
F. Selle×10
Invite
F. Selle — researcher profile on SciRah
C. Dubot×10
Invite
C. Dubot — researcher profile on SciRah

×10

Invite

A. Floquet — researcher profile on SciRah

M. Kaminsky×10

Invite

M. Kaminsky — researcher profile on SciRah

Invite

A. Leary — researcher profile on SciRah

Invite

L. Gladieff — researcher profile on SciRah

E. Pujade-Lauraine×8

Invite

E. Pujade-Lauraine — researcher profile on SciRah

Invite

P. Gesta — researcher profile on SciRah

Invite

F. Joly — researcher profile on SciRah

Invite

B. You — researcher profile on SciRah